Navigation Links
Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007

SILVER SPRING, Md., Oct. 31 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced today that they will release the results of their TRIUMPH-1 Phase 3 trial of Viveta, an inhaled formulation of treprostinil, in pulmonary arterial hypertension (PAH) before market open on Thursday, November 1, 2007.

United Therapeutics will expand its previously scheduled conference call on November 1, 2007, to a full hour to accommodate a discussion of the TRIUMPH-1 results. The call will begin at 9:00 a.m. Eastern Time. Lewis J. Rubin, MD, FCCP, Co-Chair of the TRIUMPH-1 Steering Committee and Professor of Medicine at University of California San Diego Medical Center, will join United Therapeutics' management on the call to answer questions related to TRIUMPH-1.


TRIUMPH-1 (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension), was a randomized, double-blind, placebo- controlled trial of patients with severe PAH, a chronic, life-threatening illness. The study population consisted of 235 patients who were optimized on an approved oral therapy for PAH, either bosentan (Tracleer), an endothelin receptor antagonist, or sildenafil (Revatio), a phosphodiesterase-5 inhibitor. The primary efficacy endpoint of the trial was the change in six-minute walk distance at 12 weeks measured at peak exposure, defined by the trial protocol as 10-60 minutes after inhalation of Viveta, relative to baseline.

Conference Call

United Therapeutics will host a one-hour teleconference on Thursday, November 1, 2007, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-800-603-1777, with international callers dialing 1-706-679-8129. A rebroadcast of the teleconference will be available for one week following the teleconference by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using access code 20811764.

This teleconference is also being web cast and can be accessed via United Therapeutics' website at

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life- threatening cardiovascular, cancer and infectious diseases. [uthr-g]

About Lung Rx

Lung Rx is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products.

Viveta is a trademark of Lung Rx, Inc.

Tracleer is a registered trademark of Actelion Ltd.

Revatio is a registered trademark of Pfizer Inc.

SOURCE United Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):